SI1002795T1 - HIV Replication inhibiting pyrimidines - Google Patents

HIV Replication inhibiting pyrimidines

Info

Publication number
SI1002795T1
SI1002795T1 SI9930275T SI9930275T SI1002795T1 SI 1002795 T1 SI1002795 T1 SI 1002795T1 SI 9930275 T SI9930275 T SI 9930275T SI 9930275 T SI9930275 T SI 9930275T SI 1002795 T1 SI1002795 T1 SI 1002795T1
Authority
SI
Slovenia
Prior art keywords
hiv replication
replication inhibiting
inhibiting pyrimidines
pyrimidines
hiv
Prior art date
Application number
SI9930275T
Other languages
English (en)
Slovenian (sl)
Inventor
Corte Bart De
Jonge Marc Rene De
Jan Heeres
Chih Yung Ho
Paul Adriaan Jan Janssen
Robert W. Kavash
Lucien Maria Henricus Koymans
Michael Joseph Kukla
Donald William Ludovici
Aken Koen Jeanne Alfons Van
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26805159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1002795(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI1002795T1 publication Critical patent/SI1002795T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9930275T 1998-11-10 1999-11-01 HIV Replication inhibiting pyrimidines SI1002795T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10779298P 1998-11-10 1998-11-10
US14396299P 1999-07-15 1999-07-15
PCT/EP1999/007417 WO2000027825A1 (en) 1998-11-10 1999-09-24 Hiv replication inhibiting pyrimidines
EP99203590A EP1002795B1 (de) 1998-11-10 1999-11-01 Pyrimidineihibitoren der HIV-Replikation

Publications (1)

Publication Number Publication Date
SI1002795T1 true SI1002795T1 (en) 2003-10-31

Family

ID=26805159

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930275T SI1002795T1 (en) 1998-11-10 1999-11-01 HIV Replication inhibiting pyrimidines

Country Status (41)

Country Link
US (5) US6878717B2 (de)
EP (2) EP1270560B1 (de)
JP (1) JP3635238B2 (de)
KR (1) KR100658489B1 (de)
CN (1) CN1214013C (de)
AP (1) AP1683A (de)
AR (1) AR024227A1 (de)
AT (2) ATE455107T1 (de)
AU (2) AU762523C (de)
BG (1) BG65103B1 (de)
BR (1) BRPI9915552B8 (de)
CA (1) CA2350801C (de)
CY (1) CY2008021I1 (de)
CZ (1) CZ301367B6 (de)
DE (3) DE69941934D1 (de)
DK (1) DK1002795T3 (de)
EA (1) EA004049B1 (de)
EE (1) EE05086B1 (de)
ES (2) ES2338760T3 (de)
FR (1) FR09C0004I2 (de)
HK (2) HK1025330A1 (de)
HR (2) HRP20010161B9 (de)
HU (2) HU230394B1 (de)
ID (1) ID28376A (de)
IL (2) IL143023A0 (de)
LT (1) LTC1002795I2 (de)
LU (1) LU91528I2 (de)
MY (1) MY121108A (de)
NL (1) NL300373I2 (de)
NO (3) NO318801B1 (de)
NZ (1) NZ511116A (de)
OA (1) OA11674A (de)
PL (1) PL204427B1 (de)
PT (1) PT1002795E (de)
SI (1) SI1002795T1 (de)
SK (2) SK287270B6 (de)
TR (1) TR200101306T2 (de)
TW (1) TWI238161B (de)
UA (1) UA70966C2 (de)
WO (1) WO2000027825A1 (de)
ZA (1) ZA200103769B (de)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
GB9914258D0 (en) * 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
CZ300712B6 (cs) * 1999-09-24 2009-07-22 Janssen Pharmaceutica N. V. Cásticová farmaceutická kompozice, pevná disperze a farmaceutická dávková forma, zpusoby jejich prípravy a použití a obchodní balení s jejich obsahem
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7276510B2 (en) * 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
CN100339846C (zh) * 2000-11-01 2007-09-26 斯雷普内姆斯·Com公司 对域名数据的状态变化进行实时监测并即时注册的系统及方法
US6958211B2 (en) 2001-08-08 2005-10-25 Tibotech Bvba Methods of assessing HIV integrase inhibitor therapy
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
WO2003037891A1 (en) 2001-11-01 2003-05-08 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
EA007578B1 (ru) 2001-11-01 2006-12-29 Янссен Фармацевтика Н.В. Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7767679B2 (en) 2002-03-13 2010-08-03 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
DE60333260D1 (en) 2002-03-13 2010-08-19 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
JP4300184B2 (ja) * 2002-05-03 2009-07-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ポリマー性マイクロエマルション
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
AR040456A1 (es) 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
EP1534286B1 (de) 2002-07-29 2009-12-09 Rigel Pharmaceuticals, Inc. VERFAHREN ZUR BEHANDLUNG ODER PRûVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CA2493794C (en) 2002-08-09 2010-05-25 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
JP2006508997A (ja) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Ｃｈｋ−、Ｐｄｋ−およびＡｋｔ−阻害性ピリミジン、それらの製造および薬剤としての使用
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
KR20050105190A (ko) * 2003-02-07 2005-11-03 얀센 파마슈티카 엔.브이. Ｈｉｖ를 저해하는 1,2,4-트리아진
CL2004000192A1 (es) 2003-02-07 2005-03-18 Janssen Pharmaceutica Nv Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja.
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
WO2004074244A2 (en) * 2003-02-20 2004-09-02 Smithkline Beecham Corporation Pyrimidine compounds
ES2667668T3 (es) * 2003-07-17 2018-05-14 Janssen Sciences Ireland Uc Procedimiento para preparar partículas que contienen un antiviral
CN1849318B (zh) 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
AU2004274185B2 (en) 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
AU2005218183B2 (en) 2004-03-02 2012-06-07 Virco Bvba Estimation of clinical cut-offs
EP1598343A1 (de) * 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH 2-Arylaminopyrimidine als PLK Inhibitoren
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
CN101035773B (zh) 2004-08-10 2012-06-06 詹森药业有限公司 抑制hiv的1,2,4-三嗪-6-酮衍生物
KR20070057899A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5-헤테로사이클릴피리미딘
KR20070057798A (ko) * 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
TW200626561A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-substituted pyrimidines
RU2403254C2 (ru) 2004-10-29 2010-11-10 Тиботек Фармасьютикалз Лтд. Бициклические производные пиримидина, ингибирующие вич
US20060106043A1 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating HIV infection through co-administration of tipranavir and etravirine
CA2584295C (en) 2004-11-24 2014-08-26 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1853568B1 (de) * 2005-01-27 2011-09-07 Tibotec Pharmaceuticals Hiv-inhibierende 2-(4-cyanophenylamino)pyrimidinderivate
BRPI0607455A2 (pt) 2005-02-16 2009-09-01 Astrazeneca Ab composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
ES2533258T3 (es) * 2005-02-18 2015-04-08 Janssen Sciences Ireland Uc Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH
ME01229B (me) 2005-03-04 2013-06-20 Janssen R& D Ireland 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
EP1899323A2 (de) 2005-05-16 2008-03-19 AstraZeneca AB Als tyrosinkinaseinhibitoren geeignete pyrazolylaminopyrimidinderivate
CN101248051B (zh) * 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AP2008004459A0 (en) * 2005-10-06 2008-06-30 Univ Massachusetts Composition and sythesis of new reagents for inhibition of HIV replication
MX2008005398A (es) 2005-10-28 2008-09-24 Astrazeneca Ab Derivados de 4-(3-amino-pirazol)-pirimidina para uso como inhibidores de tirosina cinasa en el tratamiento de cancer.
RS51191B (sr) 2006-01-19 2010-10-31 Janssen Pharmaceutica N.V. Derivati aminofenila kao novi inhibitori histon deacetilaze
CA2635015C (en) 2006-01-19 2014-06-03 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
AU2007206942B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2645959C (en) 2006-03-30 2016-05-17 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines
BRPI0709690B8 (pt) * 2006-03-30 2021-05-25 Janssen R & D Ireland 5-amido pirimidinas substituídas e composição farmacêutica que as compreende
AR060890A1 (es) 2006-05-15 2008-07-23 Boehringer Ingelheim Int Compuestos derivados de pirimidina y composicion farmaceutica en base a ellos
SI2029110T1 (sl) 2006-06-06 2012-01-31 Tibotec Pharm Ltd Z razprševanjem posušeni pripravki TMC125
EP2526932B1 (de) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmazeutische Zusammensetzung
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
JP5464584B2 (ja) 2006-12-06 2014-04-09 ヤンセン・アールアンドデイ・アイルランド 抗ｈｉｖ化合物の臭化水素酸塩
KR20090094084A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 5,6-치환된 피리미딘
DK2114901T3 (da) 2006-12-29 2014-06-30 Janssen R & D Ireland Hiv-inhiberende 6-substituerede pyrimidiner
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
ES2645689T3 (es) 2008-05-21 2017-12-07 Ariad Pharmaceuticals, Inc. Derivados de fósforo como inhibidores de quinasas
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
CA2727455C (en) 2008-06-27 2019-02-12 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR073760A1 (es) * 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
US20110071158A1 (en) * 2009-03-18 2011-03-24 Boehringer Ingelheim International Gmbh New compounds
EP2413936B1 (de) 2009-03-30 2016-11-02 Janssen Sciences Ireland UC Co-kristall von Etravirin und Nicotinamid
CA2760794C (en) 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2010131118A2 (en) * 2009-05-12 2010-11-18 Pliva Hrvatska D.O.O. Polymorphs of etravirine and processes for preparation thereof
JP5406934B2 (ja) 2009-06-22 2014-02-05 エムキュア ファーマシューティカルズ リミテッド ジアリールピリミジン非ヌクレオシド系逆転写酵素阻害剤の合成方法
WO2011017079A1 (en) 2009-07-27 2011-02-10 Teva Pharmaceutical Industries Ltd. Process for the preparation and purification of etravirine and intermediates thereof
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
DK2576541T3 (en) 2010-06-04 2016-05-30 Hoffmann La Roche Aminopyrimidine AS LRRK2 MODULATORS
EP2584901A4 (de) 2010-06-28 2013-10-09 Hetero Research Foundation Verfahren für etravirinzwischenprodukt und polymorphe von etravirin
SG187796A1 (en) 2010-08-10 2013-03-28 Celgene Avilomics Res Inc Besylate salt of a btk inhibitor
PE20131371A1 (es) 2010-09-22 2013-11-25 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
JP5957460B2 (ja) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド 複素環式化合物またはその使用
WO2012064706A1 (en) 2010-11-10 2012-05-18 Avila Therapeutics, Inc. Mutant-selective egfr inhibitors and uses thereof
PL3124483T3 (pl) 2010-11-10 2020-03-31 Genentech, Inc. Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2
PT2702045T (pt) 2011-04-26 2018-01-11 Mylan Laboratories Ltd Método inovador para a preparação de etravirina
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2012170647A1 (en) * 2011-06-09 2012-12-13 Assia Chemical Industriew Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
US8729079B2 (en) 2011-08-23 2014-05-20 Endo Pharmaceuticals Inc. Pyrimido-pyridazinone compounds and methods of use thereof
US20130123498A1 (en) 2011-10-19 2013-05-16 Maja Sepelj MAJER Process for the preparation of etravirine and intermediates in the synthesis thereof
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
WO2013109354A2 (en) * 2011-12-07 2013-07-25 Texas Southern University Etravirine formulations and uses thereof
RU2673077C2 (ru) 2012-03-15 2018-11-22 Селджен Авиломикс Рисерч, Инк. Твёрдые формы ингибитора киназы рецептора эпидермального фактора роста
SI2825042T1 (sl) 2012-03-15 2019-01-31 Celgene Car Llc Soli inhibitorja kinaze receptorja faktorja epidermalne rasti
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
WO2014068588A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of etravirine and its intermediates
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
AU2013362755B2 (en) 2012-12-21 2018-09-13 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
EP2935226A4 (de) 2012-12-21 2016-11-02 Celgene Avilomics Res Inc Heteroarylverbindungen und verwendungen davon
ES2805359T3 (es) 2013-02-08 2021-02-11 Celgene Car Llc Inhibidores de ERK y sus usos
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
TW201613892A (en) 2014-08-13 2016-04-16 Celgene Avilomics Res Inc Forms and compositions of an ERK inhibitor
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
CN104926829A (zh) * 2015-06-08 2015-09-23 山东大学 一种噻吩并嘧啶类衍生物及其制备方法和应用
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
EP3615032A4 (de) 2017-04-28 2020-12-23 Asana BioSciences, LLC Formulierungen, verfahren, kits und dosierformen zur behandlung von atopischer dermatitis und zur verbesserten stabilität eines wirkstoffs
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
CN111217833B (zh) * 2020-02-21 2021-03-16 山东大学 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4659363A (en) * 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
EP0172786B1 (de) * 1984-06-25 1991-01-30 Ciba-Geigy Ag Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel
EP0371139B1 (de) 1988-03-31 1994-10-12 Mitsubishi Chemical Corporation Acyclische 6-substituierte pyrimidin nukleosid-abkömmlinge und antivirale mittel, die dieselben als aktive mittel enthalten
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
JP2895680B2 (ja) * 1992-07-08 1999-05-24 シャープ株式会社 磁気ヘッドおよびその製造方法
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IL123654A (en) 1995-11-23 2001-08-08 Janssen Pharmaceutica Nv Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures
KR100219922B1 (ko) * 1996-05-16 1999-09-01 이서봉 신규한 항바이러스성 6-아릴옥시 및 6-아릴카르보닐 2,4-피리미딘디온 유도체 및 그의 제조 방법
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
DE29704863U1 (de) * 1997-03-17 1997-05-22 Gesellschaft für Innenhochdruckverfahren mbH & Co. KG, 73441 Bopfingen Achsschwinge
KR20010041015A (ko) 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
EP0945442A1 (de) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituierte Pyrimidine Derivate
ES2361146T3 (es) * 1998-03-27 2011-06-14 Janssen Pharmaceutica Nv Derivados de la piramidina inhibitatoria de vih.
ES2193660T3 (es) * 1998-03-27 2003-11-01 Janssen Pharmaceutica Nv Derivados de pirimidina inhibidores de vih.
SK287270B6 (sk) * 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
ES2559273T3 (es) * 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH

Also Published As

Publication number Publication date
HRP20080359A2 (en) 2008-12-31
EE200100252A (et) 2002-10-15
EP1270560A1 (de) 2003-01-02
NO20011696D0 (no) 2001-04-04
DE69941934D1 (de) 2010-03-04
HRP20010161B9 (hr) 2014-10-24
DE122009000003I1 (de) 2009-05-20
WO2000027825A1 (en) 2000-05-18
NO318801B1 (no) 2005-05-09
PL204427B1 (pl) 2010-01-29
NL300373I1 (nl) 2009-03-02
CN1322198A (zh) 2001-11-14
EP1002795A1 (de) 2000-05-24
CZ301367B6 (cs) 2010-02-03
ZA200103769B (en) 2002-08-12
BG105418A (en) 2001-11-30
US8530655B2 (en) 2013-09-10
US7037917B2 (en) 2006-05-02
BG65103B1 (bg) 2007-02-28
DE69905683T2 (de) 2004-03-18
US20080176880A1 (en) 2008-07-24
CZ20011533A3 (cs) 2001-10-17
ATE233740T1 (de) 2003-03-15
US8003789B2 (en) 2011-08-23
HUP0104177A3 (en) 2003-01-28
TWI238161B (en) 2005-08-21
SK6032001A3 (en) 2002-01-07
EA200100536A1 (ru) 2002-02-28
EE05086B1 (et) 2008-10-15
IL143023A0 (en) 2002-04-21
AU6200899A (en) 2000-05-29
ATE455107T1 (de) 2010-01-15
ES2193664T3 (es) 2003-11-01
CA2350801A1 (en) 2000-05-18
SK287270B6 (sk) 2010-05-07
US20030114472A1 (en) 2003-06-19
AP1683A (en) 2006-11-29
HU227453B1 (en) 2011-06-28
LTC1002795I2 (lt) 2021-06-10
KR100658489B1 (ko) 2006-12-18
KR20010075235A (ko) 2001-08-09
HK1048817A1 (en) 2003-04-17
HRP20080359B1 (hr) 2016-01-01
EA004049B1 (ru) 2003-12-25
NZ511116A (en) 2003-08-29
AU2011200708A1 (en) 2011-03-10
LU91528I9 (de) 2019-01-02
AU762523C (en) 2004-02-12
SK287269B6 (sk) 2010-05-07
PT1002795E (pt) 2003-07-31
NO2021015I1 (no) 2021-03-29
AR024227A1 (es) 2002-09-25
AU762523B2 (en) 2003-06-26
BR9915552A (pt) 2001-08-14
JP3635238B2 (ja) 2005-04-06
US6878717B2 (en) 2005-04-12
NL300373I2 (nl) 2009-04-01
FR09C0004I2 (fr) 2010-06-11
UA70966C2 (uk) 2004-11-15
NO2009003I1 (no) 2009-03-09
HUP0104177A2 (hu) 2002-03-28
PL347586A1 (en) 2002-04-08
LU91528I2 (fr) 2009-04-20
JP2002529456A (ja) 2002-09-10
IL169949A (en) 2011-02-28
HK1048817B (zh) 2010-04-09
BR9915552B1 (pt) 2013-11-19
NO2009003I2 (no) 2010-06-07
DE69905683D1 (de) 2003-04-10
DK1002795T3 (da) 2003-06-30
ID28376A (id) 2001-05-17
HRP20010161B1 (en) 2009-03-31
LTPA2008016I1 (lt) 2021-04-26
US20040039005A1 (en) 2004-02-26
HU230394B1 (hu) 2016-04-28
NO20011696L (no) 2001-04-04
EP1002795B1 (de) 2003-03-05
ES2338760T3 (es) 2010-05-12
HRP20010161A2 (en) 2002-02-28
TR200101306T2 (tr) 2001-10-22
HK1025330A1 (en) 2000-11-10
CY2008021I2 (el) 2010-07-28
OA11674A (en) 2005-01-12
US20050288278A1 (en) 2005-12-29
MY121108A (en) 2005-12-30
CN1214013C (zh) 2005-08-10
US20110263625A1 (en) 2011-10-27
BRPI9915552B8 (pt) 2021-05-25
CA2350801C (en) 2008-05-20
FR09C0004I1 (de) 2009-02-27
EP1270560B1 (de) 2010-01-13
CY2008021I1 (el) 2010-07-28

Similar Documents

Publication Publication Date Title
HK1025330A1 (en) Hiv replication inhibiting pyrimidines
AP2000001912A0 (en) Hiv inhibiting pyrimidine derivatives
EG24684A (en) HIV replication inhibiting pyrimidines
DE59902573D1 (en) Dihydropyrimidine
AU6931701A (en) Pyrimidine derivatives
AU1041802A (en) Tetrahydro-heterocycloazepinyl pyrimidine derivatives
HK1078079A1 (en) Pyrimidine derivatives
ZA992322B (en) Phosphodiesterase iv-inhibiting diazepinoindoles.
MXPA03000504A (es) Derivados de pirimidina.
DE69940886D1 (en) Hiv impfstoff
IL166937A (en) Uracil compounds
ZA200007155B (en) Uracil compounds and use thereof.
ZA200100906B (en) Uracil compounds and use thereof.
EP0954316A4 (de) Pyrimidine derivaten
IL150715A0 (en) Substituted pyrimidines
GB9810027D0 (en) Incinerator
SI1303496T1 (sl) Pirimidinski derivati